Empower Your Model Selection Strategy to Enhance Preclinical Candidate Success
Join the Community of Preclinical Experts to Accelerate the Development of
Your Therapeutic Candidates
The 8th Annual PREDiCT: Tumour Models Summit is back in London between 4-6 December to provide you with the latest progress and developments in preclinical oncology.
With 20+ cases studies, this conference is your opportunity to hear Merck, Sanofi, Basilea Pharmaceutica and more as they reveal their validation strategies behind current model selection.
New to 2019, our focus is set on showcasing the progress of I/O therapeutics to gain a better understanding of immune response and novel tumour-immune cell interactions.
New Case Studies Covering:
- Validation and selection strategies behind current in vivo models
- PDL1 and beyond: Showcase of the latest success of combination therapeutics to target tumour-immune cell interactions
- Advantages of targeting macrophages and neutrophil cells to understand how to learn more to tackle tumour resistance and the adaptive microenvironment
Join us to increase your predictability and translatability of combination therapy and improve your success in clinical trials. The discussion will help you tackle tumour resistance, model validation and the microenvironment.
Over 3 days, network and learn alongside 100+ preclinical experts and apply their expertise to improve your confidence and preclinical outcomes.
Snapshot of Companies you will hear from:
- Institut Gustave Roussy
- National Centre for Tumor Diseases
- Basilea Pharmaceutica
“This was an excellent conference and an excellent forum to network with others working at the cutting edge of cancer research.” Senior Principal
Scientist, Cancer Research Technology
“The meeting was informative, a good size and with good networking opportunities.” Preclinical Manager, e-Therapeutics
“It was a truly inspiring conference with great scientific discussions and
networking. I gained insight in addition to the publicly available knowledge.” Head of Laboratory, Merck